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was calculated. Considering a switch to aztreonam lysine, the reduction of exacerba-
tion was estimated in order to maintain the overall treatment cost. For the base case, 
ex-factory prices were considered; for sensitivity analysis, discounts ranged from 15 
to 50%. Results: Switching to aztreonam lysine would not increase overall treatment 
costs in 8/12 options; even maintaining current exacerbation episodes could lead to 
SNS savings. In the remaining options, the required reduction of exacerbations var-
ies depending on the patient’s current situation, ranging from 110% (one episode/
year) to 18% (six episodes/year). In the sensitivity analysis, there are 3 options in 
which switching to aztreonam lysine would not imply higher treatment costs. For the 
remaining alternatives, the required reduction of exacerbations does not change 
significantly from the base case: from 116% (one episode/year) to 19% (six episodes/
year). ConClusions: In CF patients with chronic pulmonary infection by PA, hos-
pitalizations costs due to exacerbations have a greater economic impact than drug 
treatment costs. Using aztreonam lysine, instead of other treatments, would not imply 
a budget impact in a wide range of patient profiles if exacerbation episodes can be 
reduced. As the number of current exacerbations increases, a lesser reduction of these 
events is required by a switch to aztreonam lysine to avoid incremental treatment costs.
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objeCtives: Meprobamate is a constituent of various combination analgesics in 
South Africa. Due to its abuse potential, the scheduling status of meprobamate is 
currently under review with the possibility of introducing stricter controls on its 
availability. The primary aim was to determine the impact of generic substitution on 
meprobamate-containing combination analgesic prescribing. Methods: A retro-
spective, cross-sectional drug utilisation study was conducted on prescription data 
of a medical insurance scheme administrator in South Africa for 2011. Results: A 
total of 97 491 analgesics were dispensed to 31 854 patients during the year. Within 
ATC category N02B, 62.10% of prescriptions were for analgesic combinations, of 
which 20 326 prescriptions were for meprobamate-containing analgesics at a cost 
of R282 930. A total of 10 404 patients received meprobamate-containing analgesics. 
Overall, 20.85% of all analgesics contained meprobamate. Patients who received 
meprobamate-containing analgesics were slightly older (39.52 years) compared 
to patients who received analgesics in general (33.61 years). Mandatory generic 
substitution exists in South Africa, unless otherwise indicated by the prescriber 
or if the patient refuses. Twenty-two trade names of meprobamate-containing 
analgesics were dispensed, of which 17 (the originator plus 16 branded generics) 
contained exactly the same dosages of active ingredients (320 mg paracetamol, 
8 mg codeine phosphate, 32 mg caffeine and 150 mg meprobamate). In previous 
studies, the originator product was the most often prescribed, yet in this study 
the originator product only constituted 3.72% of products prescribed (average cost: 
R30.42) compared to 70.63% for the most popular branded generic (average cost: 
R11.65). ConClusions: The price difference between generic equivalents and the 
originator product, together with mandatory generic substitution, were responsible 
for the change in prescribing patterns.
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objeCtives: The objective was to estimate the economic burden of B-thalassemia 
and to compare the cost of alternative iron chelation strategies in patients with 
transfusion (TDT) and non-transfusion dependent thalassemias (NTDT) in 
Greece. Methods: A multicenter, non interventional, retrospective, observational, 
phase IV study was conducted in the 3 out of 8 thalassemia units in Attica. Patients’ 
data and resource use, including medication and related consumables, blood trans-
fusions, lab tests, diagnostic examinations and hospital visits were recorded from 
January 2009 to December 2011, and classified per diagnosis and iron chelation treat-
ment strategies. Greek NHS perspective was considered. Results: 331 thalassemic 
patients were recorded whereas the majority (87.6%) was diagnosed with Beta-
thalassemia major, 31% were treated with deferasirox (DFX), 23% with deferoxamine 
and deferiprone, (DFO+DFP), 9.7% with deferiprone (DFP) and 5.1% with DFO. Patient 
mean annual cost per patient was € 32,064, including all treatment strategies, for 
the period 2009-2011, ranging from € 30,997 in 2009 to € 32,564 in 2011. Medication 
(45.9%), blood transfusions (38.1%) and consumables (14.9%) were the most impor-
tant cost drivers. Mean cost per patient treated with DFX was estimated at € 35,928, 
with DFO+DFP at € 34,035, with DFO at € 31,637 and with DFP at € 17,208 for the same 
period. DFX significantly reduced (p< 0.001) the number of blood transfusions in 
relation to DFO+DFP with 19 and 25 transfusions per year, respectively. Similarly, 
DFX significantly reduced the volume of blood transfusions (p< 0.001) in relation 
to DFO with 9,693ml and 10.312ml per year, respectively. ConClusions: Rational 
health care decision making process should be based on the holistic perspective of 
analytical resource use and disease management data rather than focusing on the 
price per product per se. Especially in Greece, a country where Beta-thalassemia 
incidence in general population is ~8 %, the consideration of all cost components 
should be taken into account in health resource allocation.
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frequency of inpatient visits and pulmonary, cardiovascular, renal and skin complica-
tions of SLE in group treated with belimumab. Therefore the use of belimumab led 
to a reduced difference in the required budget funds from 2,118,449 RUB/ 45,581 EUR 
to 1,876,965 RUB/ 40,385 EUR and the reduction ran as high as 241,484 RUB/ 5,196 
EUR for 5 years. ConClusions: The use of belimumab in the treatment of patients 
with SLE resulted in budget spending. However, a good safety profile and efficacy of 
belimumab help reduce the costs for 241,484 RUB/ 5,196 EUR for 5 years in belimumab 
treatment group.
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objeCtives: The aim of the study was to determine public expenditure on medicines 
for rare diseases from the public health sector in the Czech Republic (CZ). Methods: 
We identified orphan medicinal products (OMPs) registered by the European 
Medicines Agency (EMA) until December 2013 in the public database of EMA. In the 
base-case scenario, medicinal products available in the CZ were considered OMPs 
only within the interval of marketing authorisation date and December 2013 or OMP 
designation withdrawal date or date of withdrawal of use. Reports on consumption 
and real expenditures of these OMPs came from all health insurance companies in 
the CZ. Exchange rate of 25.4 CZK = 1 EUR was used. Results: Overall, 86 OMPs were 
authorised within the European Union (EU) between 2008 and 2013. Of these, 50 OMPs 
(58.0%) were covered from the Czech public health insurance at some point within 
this period. The number of registered OMPs increased from 54 in 2008 to 84 in 2013, 
while the number of covered OMPs doubled from 24 to 41, respectively. The annual 
public expenditure on OMPs rose simultaneously from 43 to 72 million EUR, while 
the total expenditure on drugs increased from 1.7 to 2.0 billion EUR. The OMP share of 
total pharmaceutical sales grew steadily from 2.5% in 2008, reaching 3.4% in 2011 and 
plateaued at 3.6% in 2013. Twenty-one oncological OMPs (51.2%) generated up to 72.6% 
of the overall orphan costs in 2013. ConClusions: Compared to other EU countries, 
the Czech public expenditure on OMPs of 3.6% of all drugs seems to be relatively high. 
The major part of OMP costs is in oncological diagnoses. One of the limitations is the 
exclusion of designated OMPs not authorised by EMA since these OMPs still might 
be present on the market and reimbursed. This aspect needs further investigation.
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objeCtives: The objective of this analysis was to estimate and compare the annual 
cost per patient of the administration of capsaicin 8% patch, Qutenza®, in Primary 
and Secondary Care for the treatment of adult patients with peripheral neuropathic 
pain (PNP). The annual cost per patient treated with Qutenza® was also compared 
with Pregabalin and Lidocaine in Primary Care. Methods: The costs per patient 
for each treatment were estimated by analysing the health care resources associ-
ated with the use of pregabalin, lidocaine and Qutenza®for the treatment of PNP 
from the perspective of the Spanish National Health System. Healthcare resources 
associated with the three pharmacological treatments considered were admin-
istration time and health care personnel, complementary non-pharmacological 
treatment, hospitalisation, adverse effects and concomitant medication, EUR 2013. 
Total costs per patient were estimated and compared both including and excluding 
concomitant medication to estimate the effect on the treatment costs. Results: 
The annual treatment cost per patient when Qutenza® is administrated in the hos-
pital was estimated at € 5,387.32 and € 5,259.19 when administered in Primary Care. 
Qutenza® applied in Primary Care for the treatment of PNP showed annual savings 
of € 128.14 per patient compared with the administration of Qutenza® in Secondary 
Care. Overall, the annual treatment costs per patient with pregabalin or lidocaine 
were estimated at € 14,074.14 and € 5,998.09, respectively, resulting in savings of 
€ 8,814.95 and € 738.9 respectively when compared with the annual cost per patient 
when treated with Qutenza® in Primary Care. ConClusions: The introduction 
of Qutenza® into Primary Care for the treatment of PNP is expected to result 
in annual savings due to lower administration costs associated with the use of 
Qutenza® and savings in health care personnel in Primary Care. Qutenza® also 
showed to be the less expensive option in comparison with pregabalin or lidocaine, 
independent of the area of administration.
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objeCtives: Estimate, from the Spanish National Healthcare System (SNS) perspec-
tive, the required reduction of exacerbation episodes in different patient profiles to 
maintain constant the overall treatment cost if a chronic treatment with inhaled anti-
biotics is switched to aztreonam lysine in patients with cystic fibrosis (CF) and chronic 
pulmonary infection by Pseudomonas aeruginosa (PA). Methods: A cost comparison 
model was developed considering two criteria to define patient profiles: current drug 
treatment (12 options linked to tobramycin and/or colistimethate sodium) and current 
exacerbation episodes (1-6/year). For each patient profile the overall treatment cost 
